78 results
Page 3 of 4
6-K
EX-99.2
zhq v47qsbq3xyiq
10 Dec 20
Current report (foreign)
6:03am
6-K
EX-99.1
qfcn7y8liyb g3d6lp
10 Dec 20
Current report (foreign)
6:03am
6-K
EX-99.1
n0m3k5hoo22 3g
24 Nov 20
Current report (foreign)
6:03am
6-K
EX-1.1
vrqg 1u9qd94i6x0
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am
424B5
4qv4ccuqyw3u6c837l3
8 Sep 20
Prospectus supplement for primary offering
7:31am
6-K
EX-99.1
19d sg039sggbc
14 Aug 20
Current report (foreign)
4:24pm
6-K
EX-99.1
glmcn2qn9bk58rvf
6 Aug 20
Index to Unaudited Condensed Consolidated Financial Statements
6:53am
6-K
EX-99.3
nz95d
6 Aug 20
Index to Unaudited Condensed Consolidated Financial Statements
6:53am
6-K
EX-99.1
iy97wryt96fjn0
7 Jul 20
Current report (foreign)
3:39pm
6-K
EX-99.1
hiqriz2 7qw
4 Jun 20
ObsEva Announces Publication of Data Showing Efficacy of Linzagolix in a Potential New Indication for Treatment of Adenomyosis
6:11am
6-K
EX-99.3
l2kbrd
5 May 20
Index to Unaudited Condensed Consolidated Financial Statements
6:01am
6-K
EX-99.1
l0ijcn0h
5 May 20
Index to Unaudited Condensed Consolidated Financial Statements
6:01am
6-K
EX-99.1
i8bxlraf
13 Nov 19
Index to Unaudited Condensed Consolidated Financial Statements
4:00pm
6-K
EX-99.3
0cwiz9g8ytt1t23n1
7 Nov 19
Current report (foreign)
9:11am
F-3
EX-4.1
ofj0al4ik
7 Aug 19
Shelf registration (foreign)
8:24am
424B5
4tbgifjbr89
7 Aug 19
Prospectus supplement for primary offering
8:18am
6-K
EX-99.3
ybug8qq pdbu
7 Aug 19
Index to Unaudited Condensed Consolidated Financial Statements
6:04am
6-K
EX-99.1
qzxb xz48b6elzmz68oq
7 Aug 19
Index to Unaudited Condensed Consolidated Financial Statements
6:04am